Mermaid Medical Group® Achieves Zero Non-Conformities in ISO 14001 Environmental Audit
Mermaid Medical Group® is proud to share that it has successfully passed its ISO 14001 audit with zero non-conformities identified.
Mermaid Medical Group® is proud to share that it has successfully passed its ISO 14001 audit with zero non-conformities identified.
Mermaid Medical Group is excited to introduce its latest product addition: the Full Core Biopsy Device - designed with both optimal biopsy sample quality and user ergonomics in mind.
Mermaid Medical Group® is excited to announce that our partner, Danderyd Hospital in Sweden, is now offering microwave ablation (MWA) as a treatment for uterine fibroids, following the success of several clinical studies.
As of February 2025, Mermaid Medical is offering CPD-accredited workshops focused on Local Anaesthetic Transperineal Prostate (LATP) biopsy procedures.
Following the recent UKCA approval of TP Pivot Pro™, Prof. Hashim U. Ahmed has successfully performed the first European cases of transperineal prostate biopsies with the disposable needle guide designed by CIVCO Medical Solutions.
Mermaid Medical Group® Announces Exclusive Distribution Agreement for COBRA-OS® Device in the UK for REBOA Procedures with Front Line Medical Technologies Inc.
With its recent UKCA approval, Mermaid Medical is ready to introduce the TP Pivot Pro™ to UK healthcare professionals.
2024 marks a significant milestone in our journey toward sustainability - we achieved ISO 14001 certification, underscoring our commitment to reducing our environmental footprint.
Mermaid Medical Group announces new exclusive distribution deal on the COBRA-OS® device for REBOA procedures from Front Line Medical Technologies Inc.